Analysts Set Ascendis Pharma A/S (NASDAQ:ASND) Price Target at $204.64

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have been given an average recommendation of “Moderate Buy” by the fourteen research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $204.64.

A number of research analysts have recently commented on the company. Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a report on Tuesday, February 25th. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research note on Tuesday, February 18th. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently bought and sold shares of the stock. RA Capital Management L.P. raised its stake in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company’s stock valued at $1,392,221,000 after purchasing an additional 402,316 shares during the period. Avoro Capital Advisors LLC grew its holdings in shares of Ascendis Pharma A/S by 2.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company’s stock valued at $702,538,000 after buying an additional 114,167 shares in the last quarter. Artisan Partners Limited Partnership raised its position in Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company’s stock valued at $612,689,000 after buying an additional 39,309 shares during the period. Janus Henderson Group PLC lifted its stake in Ascendis Pharma A/S by 4.6% in the 4th quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company’s stock worth $602,910,000 after acquiring an additional 193,688 shares in the last quarter. Finally, Capital International Investors boosted its position in Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company’s stock worth $394,183,000 after acquiring an additional 753,859 shares during the period.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $157.94 on Tuesday. The firm has a fifty day moving average of $143.63 and a 200-day moving average of $136.75. The company has a market cap of $9.59 billion, a price-to-earnings ratio of -22.25 and a beta of 0.62. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. Analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.